CD40L Antagonism in Rheumatoid Arthritis (RA)
| Заболевание | Rheumatoid Arthritis |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | National Institute of Allergy and Infectious Diseases (NIAID) |
| Статус | Прекращено |
| Участники | 2 участн. |
| Вмешательство | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi |
| Дата начала | 25.07.2023 |
| Дата завершения | 28.07.2025 |
| Публикация результатов | 20.07.2026 |
Кратко
The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.
Proportion of Participants Achieving Low Disease Activity by Simplified Disease Activity Index (SDAI)
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replace — Smith & Nephew, Inc.